This research develops nanoscale “smart package” delivery systems for PROTAC cancer drugs. Antibody nanogel conjugates selectively target cancer cells, enter them, and release therapeutic molecules while minimizing exposure to healthy tissue. The approach improves delivery efficiency and aims to reduce the severe side effects that often limit cancer treatment.

This research improves combination vaccines by addressing antigen competition using injectable hydrogels that slowly release antigens. This approach produces balanced immune responses to multiple diseases, unlike traditional vaccines. The innovation could reduce the number of shots required, improve global vaccine access, and ensure more effective immunization, particularly in underserved populations.